Advanced search
Publication Cover
Acta Cardiologica Volume 79, 2024 - Issue 3
Submit an article Journal homepage
71
Views
0
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Long-term safety and effectiveness of alirocumab and evolocumab in familial hypercholesterolemia (FH) in Belgium

Marc SnelDepartment of Internal Medicine, Centre of Medical Research of Jolimont Hospital, Pôle Hospitalier Jolimont, Haine Saint-Paul, Belgium
&
Olivier S. DescampsDepartment of Internal Medicine, Centre of Medical Research of Jolimont Hospital, Pôle Hospitalier Jolimont, Haine Saint-Paul, BelgiumCorrespondence[email protected]
Pages 311-318 | Received 03 Feb 2023, Accepted 01 Sep 2023, Published online: 28 Sep 2023

References

  • Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi: 10.1093/eurheartj/ehz455.
  • Stone NJ, Levy RI, Fredrickson DS, et al. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;49(3):476–488. doi: 10.1161/01.cir.49.3.476.
  • Hopkins PN, Toth PP, Ballantyne CM, et al. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol. 2011;5(3):S9–S17. doi: 10.1016/j.jacl.2011.03.452.
  • Tomlinson B, Patil NG, Fok M, et al. Role of PCSK9 inhibitors in patients with familial hypercholesterolemia. Endocrinol Metab (Seoul). 2021;36(2):279–295. doi: 10.3803/EnM.2021.964.
  • EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS familial hypercholesterolaemia studies collaboration (FHSC). Lancet. 2021;398(10312):1713–1725. doi: 10.1016/S0140-6736(21)01122-3.
  • Schludi B, Giugliano RP, Sabatine MS, et al. Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: pooled analysis of phase 2 trials. J Clin Lipidol. 2022;16(4):538–543. doi: 10.1016/j.jacl.2022.05.069.
  • Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331–340. doi: 10.1016/S0140-6736(14)61399-4.
  • Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996–3003. doi: 10.1093/eurheartj/ehv370.
  • Verdickt S, Van der Schueren B, Vangoitsenhoven R, et al. Belgian data of ODYSSEY APPRISE: stringent LDL-c targets are in reach when using all available tools. Int J Clin Pract. 2021;75(12):e14916. doi: 10.1111/ijcp.14916.
  • Toth PP, Descamps O, Genest J, et al. Pooled safety analysis of evolocumab in over 6000 patients from Double-Blind and Open-Label extension studies. Circulation. 2017;135(19):1819–1831. doi: 10.1161/CIRCULATIONAHA.116.025233.
  • Hovingh GK, Raal FJ, Dent R, et al. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11(6):1448–1457. doi: 10.1016/j.jacl.2017.09.003.
  • Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. doi: 10.1093/eurheartj/ehab484.
  • Landmesser U, Chapman MJ, Stock JK, et al. 2017 Update of ESC/EAS task force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018;39(14):1131–1143. doi: 10.1093/eurheartj/ehx549.
  • Ruscica M, Sirtori CR, Carugo S, et al. Bempedoic acid: for whom and when. Curr Atheroscler Rep. 2022;24(10):791–801. doi: 10.1007/s11883-022-01054-2.
  • Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520–1530. doi: 10.1056/NEJMoa1913805.
  • Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. doi: 10.1093/eurheartj/ehw272.
  • Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–390a. doi: 10.1093/eurheartj/eht273.
  • Descamps OS, Van Caenegem O, Hermans MP, et al. A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent Cascade screening and treatment : BEL-FaHST (the BELgium familial hypercholesterolaemia STrategy). Atherosclerosis. 2018;277:369–376. doi: 10.1016/j.atherosclerosis.2018.05.037.
  • Descamps OS, Rietzschel E, Laporte A, et al. Feasibility and cost of FH Cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy. Acta Cardiol. 2021;76(3):227–235. doi: 10.1080/00015385.2020.1820683.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.